KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Teva Pharmaceutical Industries (TEVA) Receivables - Net (2016 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed Receivables - Net for 16 consecutive years, with $3.7 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Receivables - Net rose 21.25% year-over-year to $3.7 billion, compared with a TTM value of $3.7 billion through Dec 2025, up 21.25%, and an annual FY2025 reading of $3.7 billion, up 21.25% over the prior year.
  • Receivables - Net was $3.7 billion for Q4 2025 at Teva Pharmaceutical Industries, down from $3.8 billion in the prior quarter.
  • Across five years, Receivables - Net topped out at $4.6 billion in Q1 2021 and bottomed at $3.1 billion in Q4 2024.
  • Average Receivables - Net over 5 years is $3.8 billion, with a median of $3.7 billion recorded in 2022.
  • The sharpest move saw Receivables - Net fell 20.85% in 2023, then grew 21.25% in 2025.
  • Year by year, Receivables - Net stood at $4.5 billion in 2021, then dropped by 18.39% to $3.7 billion in 2022, then fell by 7.79% to $3.4 billion in 2023, then decreased by 10.24% to $3.1 billion in 2024, then rose by 21.25% to $3.7 billion in 2025.
  • Business Quant data shows Receivables - Net for TEVA at $3.7 billion in Q4 2025, $3.8 billion in Q3 2025, and $3.6 billion in Q2 2025.